| 查看: 697 | 回复: 0 | |||
letterman新虫 (小有名气)
|
[交流]
Current drug target for Prostate Cancer
|
|
[Content] In this series, each posting will include the current or emerging drug targets for one type of cancer. [Intended audience] Students and researchers who are interested in anticancer drug discovery. Topic 1: Current drug targets and emerging drug targets for prostate cancer Prostate cancer is critically depending on the signaling of androgen receptor (AR). Current major drug target for advanced prostate cancer is the AR. There are three domains in the AR: i) The N-terminal domain (NTD); ii) DNA-binding domain (DBD); and iii) Ligand-binding domain (LBD). When the hormone (DHT) binds with AR that the LBD, the AR signaling is activated. Thus, the current strategy to inhibit the AR signaling is to develop compounds to bind with AR at the LBD (to prevent the binding of DHT with AR). Such compounds are referred to as anti-androgen and a number of such compounds have been developed into drugs, including bicalutamide and enzalutamide. However, during the treatment of anti-androgen, despite of initial response, the patients almost always become resistance to the treatment and the AR signaling is reactivated (despite of the anti-androgen treatment). While there are many possible mechanisms have been proposed, there are two key mechanisms: First, the emergence of AR splice variants that do not have the LBD confer resistance to the LBD-targeting antiandrogens. It is important to note that all of the current clinically used antiandrogens are designed to target the AR LBD; Second, the mutation in the AR LBD could confer resistance to antiandrogens. Worse yet, some mutations at the LBD could lead to the AR mutants that are activated by antiandrogensuch as enzalutamide. How to develop potent and selective inhibitors of the AR splice variants is a burning issue in the field. One approach is to target the AR NTD, but this is very challenging. The major reason is that the AR NTD is intrinsically disorder. No crystal structure of the AR NTD is available. Nevertheless, the 3rd generation of antiandrogens could be the compounds that target the AR NTD. |
回复此楼» 猜你喜欢
CSC改派-博士生交流访学
已经有19人回复
-
中山大学-第七医院-招科研助理1名（基因设计和克隆、RNA合成）
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有216人回复
-
中山大学-第七医院-招科研助理1名（基因设计和克隆、RNA合成）
已经有1人回复
-
26考博申请 学or专
已经有15人回复
-
巴黎萨克雷大学与国家留学基金委合作博士研究生项目-脂质纳米药物/生物材料/多酚递送
已经有10人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有0人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有1人回复
-
药学专硕申博
已经有1人回复
